The Board of Directors of the Company at its meeting held today i.e. Wednesday , August 13, 2025 at Registered Office of the Company has inter alia considered and approved the Un-audited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivanza Biosciences' Board approved the un-audited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). Standalone revenue from operations surged to ₹782.06 lakhs, up sharply from ₹42.78 lakhs in Q1 FY25, while total income stood at ₹783.81 lakhs versus ₹43.10 lakhs a year ago. The company posted a standalone profit before tax of ₹1.86 lakhs (vs ₹22.65 lakhs in Q1 FY25), with a marginal PAT of ₹1.86 lakhs and basic EPS of ₹0.0046. On a consolidated basis (including subsidiary Vivanza Lifesciences Pvt Ltd), revenue jumped to ₹893.92 lakhs and the company swung to a profit of ₹8.70 lakhs compared to a loss of ₹99.81 lakhs in Q1 FY25. The statutory auditor (Shivam Soni & Co.) issued an unqualified limited review report with no observations impacting the results.
Strong top-line growth and a swing back to consolidated profitability signal improving business momentum, though standalone PAT declined versus the year-ago quarter. Short-term sentiment may be positive given the revenue scale-up, but investors should watch for sustained margin recovery and subsidiary-level performance.